Answer this question, get featured on Composites Weekly

B

Business Talks WeeklyFounders & CEOs for our next Podcast Season Your journey as a founder shouldn’t just stay in the boardroom. It belongs on the screen. We are opening guest slots for our upcoming video podcast season. We’re looking for visionary Founders and CEOs in the SaaS, Fintech, E-commerce, and Healthcare space to share their "pivots and breakthroughs." Why join us? Proven Growth: Join a platform with 2.2K+ YouTube subscribers and 8.5K+ Apple Podcast streams. Multi-Channel Distribution: We don't just record; we promote. Your episode goes to Apple, Spotify, YouTube, and our newsletter of 8,000+ decision-makers. Professional Edge: For a nominal $99 production fee, you get high-end editing, social media snippets, and a seat at the table with other industry leaders. The Ideal Guest: ✅ Scaling a B2B or B2C service/product. ✅ Has "boots on the ground" insights on industry shifts. ✅ Wants to amplify their personal and company brand.

N

N.RichWe’re conducting research for the Challenger GTM Pulse 2026 (publishing name), a data-backed report exploring how B2B “challenger” companies win high-ACV, sales-led deals against better-known incumbents. Most go-to-market playbooks are written for category leaders. But what about companies fighting the giants? We’re specifically looking for insights from: B2B companies with high-touch, high-ACV sales motions (€/$30K+ ACV) Companies operating as challengers in at least one strategically important market CMOs, VP Marketing, VP Sales, CROs, Founders, and GTM leaders Please submit a response ONLY if you are willing to answer a list of questions - answers will be anonymised or published with a attribution (however you choose).

D

Drug DiscoveryFor Drug Discovery Online, I'm seeking expertise from individual scientists, SMEs, academic researchers, consultants, and executives at biotech/biopharma companies. Topic options are up to the author and their area of expertise. Some examples are new approach methodologies (NAMs), antibody-drug conjugates (ADCs), oligonucleotides (oligos), women's health in therapeutics, infectious diseases research, or the overall regulatory landscape. Our audience is comprised of professionals working in drug discovery and preclinical drug development. When responding, what are you hoping our audience will gain from this information? Here are some questions for consideration to help you get started: 1. What are the best practices or tips for implementation of your topic? 2. What are key pitfalls to avoid and what are your recommendations for overcoming them? 3. What regulatory compliance tips might you have? 4. What are emerging trends you are seeing in the space? Other intel welcome. *** We do not publish vendors or suppliers (companies that sell products or services, CROs, CDMOs). Additionally, we cannot publish content that is directly or indirectly promotional. At this time, we are unable to accept AI-generated images. Here are our writing guidelines: https://www.drugdiscoveryonline.com/doc/guest-expert-article-guidelines-0001 Drug Discovery Online is a specialized B2B digital media outlet by Life Science Connect for professionals working in drug discovery and preclinical drug development.

This deadline has passed

View Similar Opportunities